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Abstract 
 
 There are many known risk factors for chronic pain conditions. Yet the biological 
underpinnings that link these factors to abnormal processing of painful signals are only just 
beginning to be explored. This review will discuss the potential mechanisms that have been 
proposed to underlie vulnerability and resilience towards developing chronic pain. Particular focus 
will be given to genetic and epigenetic processes, priming effects on a cellular level and alterations in 
brain networks concerned with reward, motivation/learning and descending modulatory control. 
While research in this area is still in its infancy, a better understanding of how pain vulnerability 
emerges has the potential to help identify individuals at risk and may open up new therapeutic 
avenues.  
 
Introduction 
 
 Considerable advances have been made in understanding the neurobiology of chronic pain 
over the last two decades. The molecular mechanisms leading to amplification of pain-related signals 
in chronic pain states have been dissected. An unexpected contribution of non-neuronal cells in the 
CNS has been discovered, and functional as well as structural neuroimaging studies have revealed a 
brain organization and plasticity unanticipated by previous animal studies.  
 While the field is thus edging closer towards the “How”, one major unresolved question is 
“Why”, or more particularly “Why me?” A ubiquitous patient’s lament, to which neuroscience may 
be able to provide some answers. An emerging body of evidence highlights neurobiological 
processes that could render some individuals more vulnerable or more resilient to developing 
chronic pain and this will be the focus of this review.  
 There are many examples in the clinical literature demonstrating that only a proportion of 
patients with a particular disease or injury go on to develop chronic pain (Table 1):  diabetic 
neuropathy is a relatively common condition, but only a minority of patients report pain as one of 
their symptoms; a subset of individuals undergoing operations develop chronic pain (between 5% 
and 40% depending on the type of surgery); about a third of lower back pain sufferers go on to 
develop a persistent syndrome lasting for 12 months or more; and finally, quite surprisingly, no 
strong  relationship can be found between pain and joint damage in osteoarthritis, despite extensive 
study 2-5.  
 What is different between chronic pain sufferers and those that escape this fate?  
Epidemiological studies of some of the patient groups described above have identified several risk 
factors that may predispose towards the condition. Some of these are intrinsic to the individual, 
such as gender, age and genetic make-up. Women are more likely to develop certain chronic pain 
conditions, as are older people, although in some instance age may function as a protective factor. 
The influence of genetics is supported by twin and population-based studies, which clearly indicate 
that painful conditions and acute pain sensitivity per se are heritable (see Crow et al. for a recent 
review 7). Other risk factors relate to an individual’s personality and psychosocial environment. Not 
surprisingly, previous pain history predicts future pain development. But additionally, adverse life 
events, such as stress and unemployment, as well as personality traits, a tendency to catastrophize, 
and depressive illness negatively affect long-term pain outcome. While the presence of these links is 
not in doubt, cause and effect often remain unclear.  
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 It is not our intention to discuss these risk factors in any depth – the interested reader is 
referred to 2-4  - but rather to consider the mechanisms by which they may impact the emergence or 
maintenance of chronic pain (Figure 1). Their elucidation might not only help identify individuals at 
risk, but also deepen our understanding of persistent pain conditions and potentially open up new 
avenues for the development of preventative and targeted treatment regimes. 
 
Genetic risk 
 
 Human genetic studies have had a dramatic impact on many branches of medical science, 
including pain. There have been two distinct approaches which will be discussed in turn: linkage 
analysis in families suffering from rare Mendelian disorders in which single gene mutations cause 
profound loss- or gain-of-function, and association studies in large cohorts, where genetic variants 
are correlated with differences in a particular trait, such as height, or in the current context, pain 
sensitivity.  
 A number of families have been identified that show monogenic patterns of inheritance for 
sometimes dramatic pain phenotypes, such as complete analgesia or extreme pain. Congenital 
analgesia is rare, with an estimated prevalence of about one in a million, and the precise symptoms 
and underlying genetic mutations vary between families 101. Yet, their study has not only revealed 
the mechanism by which risk is conferred in these particular individuals, but has also deepened our 
understanding of chronic pain in the general population. For instance, congenital insensitivity to pain 
with anhidrosis (HSAN-IV, CIPA) is due to recessive loss-of-function mutations in the TRKA receptor 
gene (see 13 for review). This result helped consolidate pre-clinical findings which have implicated 
TRKA and its ligand NGF in nociceptor sensitization 16 and has eventually led to both targets being 
pursued by the drug development industry, with promising results: tanezumab, an NGF antibody has 
reached phase III of clinical trials for the treatment of hip and knee osteoarthritis, and may also be 
effective in other chronic pain conditions, such as back pain and interstitial cystitis (see 
http://www.fda.gov/downloads/AdvisoryCommittees/Committees 
MeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM295205.pdf). Similarly, a linkage study of 
a Chinese family in 2004 identified a completely novel target in primary erythermalgia, the sodium 
channel subunit Nav1.7 (SCN9A). Mutations in SCN9A can also cause indifference to pain and 
paroxysmal extreme pain 17. Animal studies have since confirmed the presence of Nav1.7 in 85% of 
nociceptors and its importance for processing both mechanical and inflammatory painful stimuli 17. 
Several sodium channel blockers are now in phase IIa clinical trials to test their efficacy against pain 
of diverse etiologies. Finally and most recently, another sodium channel subunit has emerged as a 
potential target, with a gain-of-function mutation having been reported in Nav1.9 (SCN11A) as 
another cause of pain insensitivity 13. 
 In contrast to rare Mendelian conditions, the study of pain genetics in the wider community 
presents a more complex picture. What everyone can agree on is that a sizable degree of risk is 
indeed accounted for by genetics:  most heritability estimates from twin studies range from 13-60% 
depending on the pain phenotype and cohort examined 7, and even in the general population they 
can reach 30% for severe chronic pain 18. As to identifying the genes responsible, the pain field has 
mostly conducted case-control candidate gene association studies that have revealed a wide variety 
of risk alleles. Loci for which a positive association has been reported are involved in 
neurotransmitter systems (COMT, OPRM1, GCH1, 5HTR2A, ADRB2), ion channel (KCNS1, CACNA2D3) 
and immune function (IL1, TNF) 101. For most of these, the mechanistic steps by which any single 
nucleotide polymorphism (SNP) or haplotype identified might confer risk towards chronic pain in 
later life are not very clear, although more functional, pre-clinical studies are beginning to emerge, 
e.g. 12, 19. More worryingly, as summarized in more detail by Mogil recently 101, results are often not 
replicable, not least because of issues with poor phenotyping, population stratification and sample 
size.  
  Recently, genome-wide association studies (GWAS) have been employed, providing unbiased 
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screening of common variants. However, many of the GWAS studies published, while examining 
painful disorders, such as osteoarthritis 20, lumbar disc degeneration 21 or endometriosis 22, barely 
mention pain in their articles, let alone measure it directly. There are notable exceptions: several 
large scale GWAS and a meta-analysis in migraine research 23; a study of molar extraction, which we 
note only examined acute post-surgical pain and may have been somewhat underpowered with only 
100 participants 24; a study of opioid sensitivity which revealed a SNP close to the CREB1 gene 25; and 
a GWAS meta-analysis of chronic wide-spread pain syndrome. The latter study merged and re-
analysed previously collected genotyping data to identify novel variants in two genes (CCT5 and 
FAM173B), the expression of which was found altered in a mouse model of pain 26. 
 What could be improved to help elucidate the genetic risk factors for chronic pain? A 
fundamental question that remains and the answer to which will greatly influence study design is 
whether many genes will be linked to nociception and pain per se (such as SCN9A). There are two, 
not mutually exclusive alternatives: risk haplotypes might differ according to the various underlying 
painful disorders, and hence future research effort should focus on GWAS such as the above-
mentioned on osteoarthritis. Conversely, genes might be more strongly linked to the various 
nociceptive modalities such as thermal or mechanical hypersensitivity, independent of the original 
source of the pain. Evidence from animal models indicates that modality can be more important 
than the underlying condition, but data from humans remains contradictory 101. In either case, 
rigorous, standardized phenotyping, e.g. using quantitative sensory testing, will be required to 
advance the field, not only for accurate pain modality assessments, but equally to help generate 
homogeneous cohorts with little stratification. Likewise, family-based designs provide greater 
protection from the latter. They can also facilitate the exploration of rare variants, by helping to 
distinguish them from sequencing errors, as evinced by a recent exome sequencing study 27, which 
found that heat pain sensitivity in twin pairs was associated with a regulatory network around 
angiotensin II. 
 Taking into account interactions, both on a phenotype and genotype level could make another 
improvement. Studies often neglect to collect phenotype data on confounding factors that could 
modulate pain, such as anxiety and depression and therefore are in danger of wrongly assigning risk 
to biological pathways unrelated to pain. Moreover, epistatic effects, i.e. interactions between 
genes, as well as interactions between genes and the environment are commonly ignored, although 
studies in mice 28 and more recently humans 29 clearly indicate that they can play an important role.  
 Finally, research into the genetics of pain should not stop at identifying the putative casual 
allele. While still rare, there now are examples of studies that move into the functional realm with 
evidence-based examination of potential biological consequences. A genome wide linkage analysis in 
mice identified a haplotype in the P2X7 receptor gene associated with strain-specific variations in 
hypersensitivity to mechanical stimuli. The authors then carried out pre-clinical work and showed 
that the risk haplotype was associated with a structural change in the ion channel pore of P2X7, 
which had consequences for nociceptive processing. Lastly, they identified a corresponding 
haplotype in humans that was associated with two distinct pain syndromes (post-surgical pain and 
osteoarthritis)30. Other instances in which studies bridge the mechanistic gap between gene and 
behaviour can be found in the brain imaging literature 31, where individual genotypes have been 
related to changes in activity in relevant cortical areas. Thus, functional polymorphisms that are 
weakly related to chronic pain syndromes might be strongly related to the integrity of the underlying 
neural systems as revealed by brain imaging. However, it is not easy to ascribe causality at this stage.  
Studies have focused on polymorphisms that influence catecholamine and serotonergic 
neurotransmission (i.e. COMT and 5-HTT and see 31 and references therein)  – reflecting a link to 
reward and the descending pain modulatory system (DPMS), which will be discussed in more detail 
below. COMT appears to be more involved in paradigms that model chronic and tonic, rather than 
acute pain and has been reported to have widespread effects on affective and cognitive tasks 
mediated by the prefrontal cortex (PFC). However, SNPs in the gene could not be convincingly 
related to overall pain risk in some genetic studies 31, and it may therefore only have relevance 
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during the expression rather than the development of chronic pain due to the PFC related effects. In 
contrast, imaging studies on serotonin receptor and transporter systems may be more promising 
with a view to identifying potential vulnerability. Neuroimaging studies that associate 5-HTT with the 
experience of pain in healthy individuals and patients are emerging and again are discussed more 
extensively in a recent review 31.  Additionally, genetic variation in 5-HTT has been linked to altered 
brain frontal-limbic network reactivity to relevant environmental stimuli and a predisposition to 
several neuropsychiatric disorders. Within the anxiety literature, it is interesting how many parallels 
with pain exist in terms of genetic polymorphisms and environmental stressors influencing PFC-
amygdala networks (see Bishop and references therein 32) that might confer vulnerability to both 
conditions. 
 
Pain vulnerability: Epigenetics 
 
 The previous section examined how differences between individuals’ DNA sequences can 
predispose towards pain, but what about differences in how this sequence is used? Epigenetics 
studies phenomena such as DNA methylation and histone modifications, which do not affect the 
sequence itself, but can affect gene function – a kind of biological annotation mechanism. Epigenetic 
signatures determine lineage-specificity during development and can be stably maintained 
throughout the life of an organism and in some cases even across generations, e.g. in the case of 
imprinting of parental alleles 33.    
 In chronic pain, some associations to epigenetic markers have recently been identified. Thus, 
altered methylation was observed at the PARK2 locus in patients with lumbar disc degeneration 21. 
Moreover, back pain was also found to be linked to methylation changes at the SPARC gene in both 
humans and mice 34.  
 It is currently not clear how much of this putative variation is present from birth and how 
much is acquired later. Until a decade ago, dogma on DNA methylation maintained that, in healthy 
tissues, the modification remained mostly unaltered postnatally. However, research since has 
identified mechanisms for active DNA demethylation 35, and evidence is accumulating to suggest 
that both DNA methylation and histone modifications can change rapidly in an adult organism, even 
in a postmitotic environment 36. Epigenetic modifications may therefore provide a way in which 
environmental influences can leave a long-term imprint on gene expression. The idea, first proposed 
by so-called behavioral epigeneticists, has encountered a healthy level of skepticism 37, but is gaining 
traction from research in many other fields, including normal brain function, aging, and a variety of 
disorders such as neurodegeneration and chronic pain 38, 39. In the current context, the hypothesis is 
that injury or disease might result in a type of molecular memory that could affect a person’s risk of 
developing chronic pain at a later stage.  
 Evidence in support of this hypothesis is starting to emerge slowly. Histone modifications 
seem to play a role in both inflammatory and neuropathic pain conditions, as evinced by the 
analgesic effect of histone deacetylase inhibitors – drugs that interfere with the removal of histone 
acetyl groups 39, 40.  There are also first indications that changes in histone modification may 
correlate with changes of expression of relevant genes 7, although the direction of causality remains 
unclear, as does the biological significance of histone marks at individual genetic loci 41. In the case 
of DNA methylation, one early drug study, using a DNA methyltransferase inhibitor, reported 
alleviation of hypersensitivity after chronic constriction injury 42. However, these results are 
inconclusive, due to their use of a compound unable to act on postmitotic cells 43. Correlational work 
has been carried out, linking global changes in DNA methylation in the PFC and amygdala to 
peripheral nerve injury 44, and examining local alterations in DNA methylation at several genetic loci 
7, 45. Again, cause and consequence are unknown. Finally, the most substantial body of work has 
been conducted around the methyl-CpG-binding protein 2 (MECP2), an enzyme crucial to neuronal 
development, which binds to methylated cytosine-phosphate-guanine motifs (CpGs). MEPC2 is 
downregulated after nerve injury in the dorsal root ganglia, its targets upregulated in the spinal cord 
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after peripheral inflammation 46, and mutations in its sequence can lead to abnormal pain sensations 
in patients 47. Work from Skene et al. has suggested that MECP2 binds neuronal DNA very widely and 
might function as a global regulator of chromatin remodeling, recruiting co-repressors to the right 
place at the right time, thereby reducing transcriptional noise 48. One could therefore hypothesize 
that even subtle differences in MECP2 function might have noticeable consequences and could, at 
least in theory, be at the root of inter-individual differences in phenotype.   
 To summarize, the literature on pain and epigenetics is still in its infancy. Only a small number 
of papers have been published so far and, not surprisingly for such a novel field, some of them still 
suffer from basic technical issues. These include lack of negative controls for chromatin 
immunoprecipitation and use of compounds better suited to dividing cell systems. What does seem 
clear is that persistent pain states are associated with epigenetic modulation of histones or DNA, and 
that drugs targeting epigenetic processes can modify pain processing. What is unknown is whether 
long-term vulnerability or resilience for pain arises from these processes. For future work, the cell-
type specificity of epigenetic marks will be a major task to address, especially when it comes to DNA 
methylation studies in humans. In the case of histone modifications, timescales, especially in post-
mitotic cells, and precise function still need to be elucidated. It may be worthwhile to bear in mind 
evolutionary conservation 49 and the high degree of redundancy when considering their biological 
significance. Long-term risk for chronic pain may be more likely to be conferred by differences in 
DNA methylation, arguably one of the most stable epigenetic marks. Focus should be on studying 
cell-specific models in which causality can be established. New compounds for the study of 
epigenetics are continually emerging and may greatly aid this work.  
 
Priming mechanisms 
 
 The previous section has argued that epigenetic mechanisms might confer risk for chronic pain 
by functioning as a type of molecular memory – a record of prior injury or disease that may 
adversely affect future responses to similar insults. But is there any evidence that such a priming 
mechanism does indeed exist in chronic pain? There are several lines of research that indicate that 
early life stressors or even previous injury in adulthood can make an animal more vulnerable to 
develop persistent pain. We will discuss postnatal experiences and adult priming in turn.  
 Pain exposure in early life can lead to heightened pain sensitivity once the animal has fully 
developed. This has been shown for diverse stimuli, such as neonatal chronic footshock, 
inflammation and incision (see 50 and references therein). Moreover, not just pain, but also early-life 
stress seems sufficient to induce hypersensitivity in later life. Thus, maternal separation can lead to 
increased visceral hypersensitivity in adult rats 51 and mice 52. Many potential mechanisms have 
been proposed for these phenomena, including alterations to the opioid system, increased axonal 
sprouting or NGF-induced neuronal plasticity, involvement of the hypothalamic-pituitary-adrenal 
axis and of spinal microglia 50, 53, 54. Most recently, imaging data have confirmed these pre-clinical 
findings. Studies on preterm infants examined at various time-points after hospital discharge 
confirm that alterations in brain processing occur and that this impacts cognitive outcomes 55 and 
brain reactivity specifically to painful events 56. 
 In adulthood, priming has been induced using low dose inflammatory stimuli that ordinarily 
only result in short lasting hypersensitivity. When a rat is administered two consecutive low doses, 
the second one will cause longer-lasting (days rather than hours) and more pronounced 
hypersensitivity (see Figure 1B). Priming can be observed with diverse inflammatory mediators, such 
as prostaglandin E2, serotonin and NGF, and with stress caused by unpredictable sound 57. The 
phenomenon has also been reported with other paradigms employing repeated nerve injury, stress 
prior to nerve injury or formalin- and injury-induced enhancement of pain following intrathecal 
lipopolysaccharide (LPS) injection (see 58 and references therein). Mechanistic explorations of 
priming fall into two main categories, focusing on peripheral afferents and spinal microglia, 
respectively. Experiments from the Levine laboratory indicate that the priming stimulus activates an 
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additional PKC-mediated second messenger cascade in isolectin B4-positive peripheral afferents. 
This in turn recruits the cytoplasmic polyadenylation element binding protein (CPEB), a regulator of 
protein translation, which is then hypothesized to render nociceptors more responsive to pro-
inflammatory cytokines 59. A second strand of work studied alterations to microglial responses in the 
spinal cord, following the induction of priming 58. For example, minocycline, an inhibitor of microglial 
activation, was found to reduce priming induced by LPS injections in the rat.  
  
 
‘Vulnerable’ Brain Networks  
 
 Having discussed possible molecular and cellular risk factors, it is important to now ask 
whether brain networks play a role. The concept that differences in brain function relate to both 
individual variances in behavior and perhaps a ‘vulnerability’ towards or ‘resilience’ against causing a 
diseased or chronic pain state is not new outside the pain field 32, 60, 61. However, data are relatively 
sparse, as firm agreement on what a “normal brain” looks like and how networks relate to 
mechanisms is lacking. Moreover, the traditional approach in brain imaging is to group average 
results, and hence smooth out any variances.  Despite these caveats, discussed in more detail in Text 
Box 1, there are several studies reporting inter-individual differences in brain activity, structure, 
wiring and chemistry. They specifically relate to endogenous modulatory capacity 62, psychological 
traits 63, pain thresholds in healthy subjects 64, 65 and patients 66, clinical descriptors 67 or opioid 
analgesic outcomes 68.  
 What remains unclear is whether these brain correlates of trait and behavioral variance in 
healthy subjects translate into an increased likelihood for developing chronic pain. Understanding 
whether changes in brain networks are consequential to having chronic pain or causal in producing it 
is very difficult and relies on detailed, longitudinal knowledge of biological and environmental 
subject variables. We lack a definitive answer, but data discussed here suggest there might be 
several candidate ‘causal’ networks, summarized in Figure 1C. We will focus our discussions on the 
reward-motivation-learning network and the DPMS.  
 The reward-motivation-learning network 
A recent study from Baliki and colleagues 69 comes closest to performing the ‘pre- to post injury’ 
longitudinal imaging study that is ideally needed.  They performed a longitudinal brain imaging study 
of subacute back pain patients over the course of one year using a battery of brain imaging 
measures from the acute pain phase onwards. Pain persisted in twelve patients at the one-year time 
stamp, while twelve patients improved. In the persistent pain group, gray matter density was 
decreased, as shown to occur in other chronic pain conditions. But of particular relevance are the 
results from the first ‘baseline’ imaging session during the acute pain phase. Here, greater functional 
connectivity or ‘coupling’ of the nucleus accumbens (NAc) with the PFC predicted pain persistence 
by more than 80%. This implies that corticostriatal circuitry might be causally involved in the 
transition from acute to chronic pain. Interestingly, this increased coupling remained constant 
throughout the transition to chronic pain despite gray matter density decreasing within the NAc. In 
an additional analysis the authors discovered brain white matter connectivity differences within the 
PFC at an early time point, which again was more pronounced in the group that went on to develop 
chronic pain. These changes may reflect structural ‘vulnerabilities’, as measured by diffusion tensor 
imaging (DTI) and fractional anisotropy (FA) calculations. Importantly, as with the functional 
connectivity measures, these white matter FA differences accurately predicted pain persistence over 
the next year, and this was validated in a second cohort of subacute back pain patients 70. While it is 
unknown whether these differences in function and structure were present pre-injury and hence 
represent an a priori risk for pain, this study nevertheless highlights how the brain's reward-
motivational learning circuitry is potentially relevant in predicting the transition from acute to 
chronic pain. In an earlier study, Baliki and colleagues had already reported results that hinted at a 
possible ‘bias’ in the reward network prior to chronic pain development 71. That study showed 
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differential NAc responses to acute noxious thermal stimuli in controls and chronic back pain 
patients implying an altered valence to acute pain exists between patients and controls. 
Indeed, studies in the past have noted the relevance of reward circuitry in pain 72, and other 
related networks, such as those relevant to dopaminergic signaling, have also been involved. Thus, 
patients with fibromyalgia have disrupted dopaminergic reactivity 73. Further, placebo analgesia in 
healthy controls can be predicted by dopamine-related traits, with its magnitude correlated to gray 
matter density in the insula, ventral striatum, and PFC 74. A link between the ability to experience 
analgesia and the brain reward network is also supported by findings from our laboratory. Baseline 
responses to a painful stimulus were found in reward networks, involving for example the ventral 
tegmental area and the NAc. This baseline activity was predictive of both subsequent opioid induced 
behavioral analgesia and its neural expression via the DPMS 68.  
 Despite these fascinating results, the precise role of the reward-motivation-learning system 
in pain remains unclear and may depend on context. We showed that the hedonic value of pain can 
be ‘flipped’, fundamentally altering its emotional value from threat to reward. This change was 
mediated by activity in reward regions working in concert with the DPMS 75, providing further 
evidence for the importance of these networks in pain appraisal – a key feature of ongoing, chronic 
pain states. Dispositional optimism and pessimism, key trait factors relevant in pain, powerfully 
influence unexpected reward/analgesia outcomes with diametrically opposite NAc activity 
distinguishing the pessimists from optimists (discussed in 75. Combined with data already discussed, 
it seems likely that transition to and continuation of chronic pain is dependent on the state of 
motivational/learning and reward mesolimbic-prefrontal circuitry of the brain. 
The descending pain modulatory system (DPSM) 
The DPMS is a powerful network that regulates nociceptive processing within the dorsal horn of the 
spinal cord and thereby controls what signals enter the brain. As such it plays a significant role 
influencing what pain you ultimately experience 8, 76. The brainstem’s component of the DPMS 
involves, among other nuclei, the periaqueductal gray (PAG) and the rostral ventromedial medulla 
(RVM). There is bidirectional central control of nociception that can either alleviate pain in situations 
where antinociception is necessary for survival (driven by “off” cells), as in sporting competition or 
battle, or can facilitate nociceptive processing (driven by “on” cells) and thereby contribute to the 
maintenance of heightened pain states. This was confirmed recently in several brainstem-imaging 
studies of chronic pain and central sensitization, a key dorsal horn event that amplifies incoming 
nociceptive inputs 77. The anterior cingulate cortex, amygdalae and hypothalamus are also part of 
the DPMS, and these connections to the brainstem are the means by which cognitive and emotional 
variables interact with nociceptive processing to influence the resultant pain experienced, as shown 
in a wealth of brain and spinal cord imaging studies 78-80. Neurochemically, the DPMS releases 
noradrenaline (NA) and 5-hydroxytryptamine (5-HT) on to spinal circuits. NA acts through its 
inhibitory alpha-2 adrenoceptor to inhibit, whereas 5-HT has bidirectional effects – inhibiting via 5-
HT1 receptors and facilitating when 5-HT2 or 5-HT3 receptors are activated at spinal levels 8. The 
polymorphisms in 5-HTT discussed earlier that influence pain outcomes are likely mediated via this 
system. Further, disturbances in sleep or mood, as well as early life stressors that are known to 
relate to neuroticism and anxiety could have profound developmental influences on this key system 
via alterations in the coupling of the amygdala-PFC network to the brainstem nuclei. Such an 
unfavorable ‘imbalance’ in inhibitory and facilitatory (i.e. off/on cell) drive could therefore 
predispose individuals towards developing persistent pain. Supporting data for this hypothesis 
comes from both recent animal and human studies.  
One experiment measured patients’ responses to painful stimuli in a laboratory setting and 
showed that results from certain tests could be used to predict acute pain after thoracotomy surgery 
81. Most predictive was pain temporal summation, i.e. an individual’s level of pain in response to a 
series of heat stimuli. This measure is thought to be mediated by central processes like the DPMS 
and may represent ‘neuroplasticity potential’. An alternative manipulation thought to tap into latent 
DPMS function via ‘diffuse noxious inhibitory control’ (DNIC) mechanisms is ‘conditioned pain 
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modulation’ 82, which Yarnitsky and colleagues showed could be used to predict lower risk of chronic 
post-thoracotomy pain 83. In a more recent study, they found that poor DNIC efficiency predicts 
duloxetine efficacy in painful diabetic neuropathy 84. Duloxetine targets the serotonergic and 
noradrenergic brainstem systems central to the DPMS and even ‘corrected’ the aberrant DNIC 
efficiency. While no imaging counterpart to these studies has been performed to verify the neural 
network ‘at risk’, it is highly likely defects in the DPMS inhibitory/facilitatory arms will be identified 
and relate to chronic pain transition.  
In fact, animal studies suggest that this might be the case. Porreca’s group has collected 
evidence to suggest that changes within the DPMS are crucial to the persistent nature of pain in 
models of nerve injury. They found that post injury decreases in descending inhibitory and increases 
in descending facilitatory activity on dorsal horn processing strongly influenced whether chronic pain 
behavior was maintained (and opposite for improved pain symptoms) 85, 86.  Knowing whether such 
an imbalance pre-exists ahead of injury is key, and evidence from neonatal rat studies might shed 
light on this issue. Hathway and colleagues showed, in a series of experiments that up to rat 
postnatal day 21, the RVM exclusively facilitates spinal pain transmission. However, after this age 
(postnatal day 28 to adult), its influence shifts to biphasic facilitation and inhibition 87. These data 
hint at the possibility that should there be damage at a critical period of development (e.g. through 
stress or injury), it could permanently influence the ‘set point’ of the DPMS and possibly pain 
network maturation. The authors also demonstrated that there is another critical period for DPMS 
functioning during preadolescence 88, where a developmental transition from RVM descending 
facilitation to inhibition of pain occurs, which is determined by activity in central opioid networks. 
Their subsequent work showing how early life nerve injury produces a mechanical hypersensitivity 
only later in life is intriguing in the light of these findings 89. 
In sum, these results lead us to the following hypothesis (yet to be tested): early life injury 
may create an imbalance in the DPMS, leading to inappropriate inhibition or facilitation of ascending 
pain signals. This in turn may create vulnerability and, as such, impact the maintenance of chronic 
pain states. 
 
Hormones and the adolescent brain – a vulnerable time?  
As noted from the animal studies above, there is a critical period of development during 
preadolescence. Although imaging studies examining how hormones generally influence brain 
activity are scarce, those published to date hint at the possibility that adolescent brains might be 
rendered vulnerable at this stage of hormonal upheaval 90. Results support a link between the stress 
system and the DPMS, with one study showing that testosterone influences DPMS activity during 
altered estradiol states 91. Other studies showed that repeated episodes of pain associated with 
menstruation throughout adolescence and early adulthood can be linked to central sensitization, 
alterations in brain function, structure and duration 92, 93. A related line of research explores how sex 
differences might confer differential vulnerability, and several studies show significant sex-related 
structural differences in pain related regions 94. This whole area is fertile for further exploration and 
we believe will play an increasingly important role in ‘brain pain-vulnerability’ related questions. 
 
Can we outline a causal trajectory from aberrant brain activity? 
As mentioned previously, a major caveat of the literature to date is its failure to identify 
causality. In addition to the studies already described that focus on the reward and DPMS networks, 
other studies are also trying to address this issue. They are still restricted to the injured state, but 
are taking a different approach and attempting to characterize whether ‘non-pain’ related features 
are present that correlate with differential brain activity or structure compared to controls.  For 
instance, researchers have examined the contribution of a potential pre-existing vulnerability due to 
neuroticism, a stable personality trait characterized by a propensity for negative affect. Neuroticism 
was found to be positively correlated with increased thickness in the orbitofrontal cortex, an area 
linked to TMD-associated pain 95. Similarly, a correlation between white matter connectivity strength 
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and neuroticism has been found in irritable bowel syndrome (IBS). And finally, IBS patients with a 
tendency to catastrophize their pain showed reduced dorsolateral PFC cortex thickness and 
increased hypothalamic grey matter (see 96 and references therein). These studies suggest that an 
individual’s personality might be associated with differential brain structure and connectivity in 
areas relevant to chronic pain and that this might constitute vulnerability prior to the development 
of the condition that contributes to emergence and/or maintenance of the chronic pain state.  
An additional phenomenon that has been examined in this context is attentional focus in the 
face of competing stimuli (e.g. having to perform a challenging cognitive task while experiencing 
pain). Thus, a recent study from Erpelding and Davis 97 classified subjects as ‘pain focused’ or 
‘attention focused’. Whether their data reflect vulnerability towards developing chronic pain 
remains to be determined, but promising parallels can be drawn to the anxiety literature. There, we 
know that frontal brain regions are involved in attentional regulation of emotionally and non-
emotionally salient stimuli, including the dorsal and ventrolateral PFC and the rostral and dorsal 
anterior cingulate cortices. Some of these areas were differentially regulated in Erpelding and Davis’ 
experiment, suggesting potential vulnerability in emotion regulation.  
 
Conclusions 
 
 The literature leaves little doubt that certain groups of people are more vulnerable to 
develop chronic pain conditions.  Evidence and viable hypotheses can be found as to why genetics 
and adverse priming events, such as a prior injury or stressful environmental influences, may confer 
increased risk. The latter may involve changes to neuronal architecture and molecular processes via 
epigenetic modulation that ultimately lead to changes in cortical wiring, brain chemistry, function 
and structure. Whether measureable alterations in brain function precede and/ or follow the onset 
of chronic pain, they might lead to a vicious cycle where ‘vulnerability’ leads to ‘non-resilience’ to 
additional factors arising from the chronic pain state. Possible support for this comes from several 
studies showing accelerated gray matter loss in chronic pain patients as if undergoing premature 
aging 98.  
The characterization of brain imaging signatures in pain-free individuals prior to any injury 
will be crucial if we are to identify the relevant ‘vulnerable’ networks. Two current large-scale 
projects afford this opportunity: the UK’s Imaging Biobank (http://www.ukbiobank.ac.uk) and The 
Human Connectome Project (http://humanconnectome.org).  They are designed to use advances in 
neuroimaging, while simultaneously collecting in depth phenotypic and genotypic data from cohorts 
of healthy subjects, and in some instances following subjects longitudinally. Their outcome will 
provide a rich platform for future investigations linking structural and functional vulnerability and 
resilience to disease. They should also afford the chance to develop early-life interventions for 
improved well-being or better ‘brain resilience’, as perhaps illustrated in a recent study highlighting 
the benefits of yoga on brain circuits linked to increased pain tolerance 99.  
 The desire to identify and understand the biological underpinning of risk factors is often 
motivated by the hope for more targeted or preventative treatments. Indeed in the case of chronic 
pain it may be possible to use a combination of brain related measures, quantitative sensory testing 
and genotyping to aid stratification and improve treatment selection and targeting of interventions. 
We are not there yet, but recent imaging data points towards this being feasible 68. Finally though, it 
is important to remember that stochastic and non-linear, chaotic processes have a major role to play 
in a person’s life. Smoking causes cancer, but is neither a necessary nor a sufficient factor 100. The 
goal of predicting who will develop chronic pain and who will be spared is a worthy one, but 
whether this is achievable at an individual level remains to be seen.  
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Text Box 1: Brain Networks for Pain and its Modulation 
It is tempting to hypothesize that all networks subserving the emergence of pain perception and its modulation 
might contribute to the vulnerability towards or resilience against chronic pain development. However, most data 
come from pain studies in healthy controls and use repeated and short lasting stimuli more akin to acute pain. The 
networks identified might not always relate to chronic pain or be incomplete, as evinced in recent studies 1. 
Advances in our ability to image within an individual ongoing or tonic pain states more relevant in chronic pain have 
occurred and look promising despite the technical and analytical challenges 6. Such studies will provide additional 
opportunities to identify relevant ‘vulnerable’ networks. 
Alongside these identified caveats, it should also be noted that brain imaging is not simply a surrogate ‘objective’ 
measure of pain ratings, but rather a very powerful tool for aiding the explanation behind why a subject reports 
their pain in a specific way. It can shed light on the many processes and factors that ultimately give rise to the 
individual experience of pain; namely an identifiable and measurable nociceptive drive, the immediate context, a 
person’s emotional and cognitive state – and perhaps in future, an individual’s brain vulnerability. 
Interpretation is key, and most studies have been careful to use paradigms that dissect the activity from a complex 
network of responsive brain regions to associate regional activity with the various components that make up the 
multidimensional pain experience. Thus, non-specific responses in regions with roles in e.g. attention, expectation, 
anxiety and other emotions can be better understood neuroanatomically and in light of their contribution to pain 
experiences 8-10. Therefore, the fact that many of the brain regions found active are not pain specific is not a new 
concept, and recent studies again highlight this point, but argue for the non-specificity to be considered instead as a 
brain network encoding the saliency of pain due to its predominance amongst many stimuli 11. 
The advent of non-invasive tools has nevertheless been invaluable in increasing our understanding of the brain 
regions that subserve the private, multidimensional experience of pain. The current framework for the neural basis 
of pain perception includes a large bilateral network that is potentially available for activation - summarized in 
Figure 1C. Its different components can show varying levels of activation and can be recruited for activation (or not) 
in a dynamic fashion contingent on nociceptive drive, context, cognition, and emotion. If any of these factors 
change, the same nociceptive input can produce a different cerebral signature within the same subject, even 
stimulus by stimulus. Therefore, the behavioural reaction to such pain experiences is very efficient, being based on a 
rapid and adaptive brain response that is tailored to specific situations 8.   
 Additionally, this large network can be broken down into multiple interacting pain matrices of increasing neural 
hierarchy, as recently put forward by Garcia-Larrea and Peyron 14. Multivariate pattern analysis has been used in an 
attempt to simplify this complex set of interacting networks to a core set of brain regions or a generalizable “pain 
signature”. Such approaches identify the following areas as key to experiencing pain: the thalamus, the posterior 
and anterior insulae, the secondary somatosensory cortex, the anterior cingulate cortex and the periaqueductal 
gray matter 15 – still a complex pattern with the specificity question unresolved. Whether network differences in the 
acute or chronic pain networks are causal towards or consequential of chronic pain is not yet known. However, data 
from recent studies, and discussed in this review, suggest that several networks, including the reward-motivation-
learning and descending pain modulatory system, might be aberrant pre-injury and confer a vulnerability towards 
developing chronic, persistent pain. 
11 
 
 
 
 
 
 
 
 
 
 
 
 
Patient 
Statistics  
Condition/Surgery Incidence 
Diabetes 15,692  Total incidence of neuropathy   48% 
Painful neuropathy 34% 
Postsurgical pain 159,000 Amputation 30-50% 
 479,000 Breast surgery 20-30% 
 unknown Thoracotomy 30-40% 
 609,000 Inguinal hernia repair 10% 
 598,000 Bypass surgery 30-50% 
 220,000 Caesarean section 10% 
Lower back pain 448  Pain 5 years after first presentation – 
prospective study 
36.9% 
 180  Pain 12 months after initial consultation – 
prospective study 
34% 
Neck Pain 5277  Incidence of chronic neck pain in cohort of 
patients reporting at least one episode of acute 
neck pain – prospective study 
18% 
Table 1: Examples of studies examining the emergence or incidence of chronic pain  
Only a minority of acute pain sufferers, disease affected and surgical patients will develop chronic 
pain 2-4. 
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Figure 1: Risk factors for chronic pain, their potential mechanisms and biological underpinnings.  
Various risk factors have been identified for chronic pain, such as genetic, environmental 
and personality factors (left panel). Evidence for potential mechanisms underpinning these 
risk factors (middle panel) as well as their biological consequences (right panel) is beginning 
to emerge.  
(A) Polymorphisms in the DNA sequence and epigenetic mechanisms such as DNA 
methylation and histone modifications determine some risk from birth that can lead to 
transcriptome and connectivity differences. Shown here is a schematic of DNA with two 
single nucleotide polymorphisms (SNPs in red) and modified by methylation (Me) at a CpG 
island. The DNA is wrapped around a histone octamer consisting of two H2A-H2B histone 
dimers and one H3-H4 histone tetramer, the lysine residues of which can be biochemically 
modified. Represented here are phosphorylation (P), acetylation (Ac) and methylation (Me). 
(B) Environmental influences have been shown to cause changes at the cell biology level 
that may be consolidated through epigenetics to cause priming of the nociceptive system. 
Shown here is a putative intracellular cascade initiated by repeated prostaglandin E2 (PGE2) 
injection into a rat paw. PGE2 binds the ephrin receptor (EP-R), and in a primed state causes 
activation of protein kinase C epsilon (PCKε), which then may have transcriptional effects via 
the cytoplasmic polyadenylation element-binding protein (CPEB). In a primed state, pain 
intensity and duration in response to a nociceptive stimulus are increased compared to the 
naive situation.  
(C) Many brain regions and networks contribute to normal and chronic pain experiences 
(red regions). Various brain networks may be involved in conferring vulnerability to painful 
conditions, in particular the reward-motivation network (purple regions) and the descending 
pain modulatory system (green regions). Evidence has been found for differences in 
structure, wiring, function and neurochemistry. (rACC/mACC (rostral/medial anterior cingulate 
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cortex); vlPFC (ventrolateral prefrontal cortex); dlPFC (dorsolateral prefrontal cortex); mPFC (medial 
prefrontal cortex); OFC (orbitofrontal cortex); insula/S2 (insular and secondary somatosensory 
cortex); S1 (primary somatosensory cortex); NAc (Nucleus accumbens); Am (amygdala); Hip 
(hippocampus); Hypo (Hypothalamus); Thal (thalamus); PAG (periaqueductal gray); RVM (rostral 
ventromedial medulla); VTA (ventral tegmentum) and Cerbllm (cerebellum)).  
 
References 
 
1. Hashmi, J.A. et al. Shape shifting pain: chronification of back pain shifts brain 
representation from nociceptive to emotional circuits. Brain : a journal of neurology 
136, 2751-2768 (2013). 
2. Kehlet, H., Jensen, T.S. & Woolf, C.J. Persistent postsurgical pain: risk factors and 
prevention. Lancet 367, 1618-25 (2006). 
3. Dieppe, P.A. & Lohmander, L.S. Pathogenesis and management of pain in 
osteoarthritis. Lancet 365, 965-73 (2005). 
4. Balague, F., Mannion, A.F., Pellise, F. & Cedraschi, C. Non-specific low back pain. 
Lancet 379, 482-91 (2012). 
5. Abbott, C.A., Malik, R.A., van Ross, E.R., Kulkarni, J. & Boulton, A.J. Prevalence and 
characteristics of painful diabetic neuropathy in a large community-based diabetic 
population in the U.K. Diabetes Care 34, 2220-4 (2011). 
6. Segerdahl, A.R. et al. Imaging the neural correlates of neuropathic pain and 
pleasurable relief associated with inherited erythromelalgia in a single subject with 
quantitative arterial spin labelling. Pain 153, 1122-7 (2012). 
7. Crow, M., Denk, F. & McMahon, S.B. Genes and epigenetic processes as prospective 
pain targets. Genome Med 5, 12 (2013). 
8. Tracey, I. & Dickenson, A. SnapShot: Pain perception. Cell 148, 1308-1308 e2 (2012). 
9. Ploghaus, A. et al. Dissociating pain from its anticipation in the human brain. Science 
284, 1979-81 (1999). 
10. Bushnell, M.C., Ceko, M. & Low, L.A. Cognitive and emotional control of pain and its 
disruption in chronic pain. Nature reviews.Neuroscience 14, 502-511 (2013). 
11. Mouraux, A., Diukova, A., Lee, M.C., Wise, R.G. & Iannetti, G.D. A multisensory 
investigation of the functional significance of the "pain matrix". Neuroimage 54, 
2237-49 (2011). 
12. Malfait, A.M. et al. A role for PACE4 in osteoarthritis pain: evidence from human 
genetic association and null mutant phenotype. Ann Rheum Dis 71, 1042-8 (2012). 
13. Cox, J.J. & Wood, J.N. No pain, more gain. Nat Genet 45, 1271-2 (2013). 
14. Garcia-Larrea, L. & Peyron, R. Pain matrices and neuropathic pain matrices: a 
review. . Pain in press (2014). 
15. Wager, T.D. et al. An fMRI-based neurologic signature of physical pain. N Engl J Med 
368, 1388-97 (2013). 
16. McMahon, S.B. NGF as a mediator of inflammatory pain. Philos Trans R Soc Lond B 
Biol Sci 351, 431-40 (1996). 
17. Eijkelkamp, N. et al. Neurological perspectives on voltage-gated sodium channels. 
Brain 135, 2585-612 (2012). 
18. Hocking, L.J., Morris, A.D., Dominiczak, A.F., Porteous, D.J. & Smith, B.H. Heritability 
of chronic pain in 2195 extended families. Eur J Pain (2012). 
14 
 
19. Tsantoulas, C. et al. Sensory neuron downregulation of the Kv9.1 potassium channel 
subunit mediates neuropathic pain following nerve injury. J Neurosci 32, 17502-13 
(2012). 
20. arcOgen Consortium et al. Identification of new susceptibility loci for osteoarthritis 
(arcOGEN): a genome-wide association study. Lancet 380, 815-23 (2012). 
21. Williams, F.M. et al. Novel genetic variants associated with lumbar disc degeneration 
in northern Europeans: a meta-analysis of 4600 subjects. Ann Rheum Dis (2012). 
22. Nyholt, D.R. et al. Genome-wide association meta-analysis identifies new 
endometriosis risk loci. Nat Genet 44, 1355-9 (2012). 
23. Esserlind, A.L. et al. Replication and meta-analysis of common variants identifies a 
genome-wide significant locus in migraine. Eur J Neurol 20, 765-72 (2013). 
24. Kim, H., Ramsay, E., Lee, H., Wahl, S. & Dionne, R.A. Genome-wide association study 
of acute post-surgical pain in humans. Pharmacogenomics 10, 171-9 (2009). 
25. Nishizawa, D. et al. Genome-wide association study identifies a potent locus 
associated with human opioid sensitivity. Mol Psychiatry (2012). 
26. Peters, M.J. et al. Genome-wide association study meta-analysis of chronic 
widespread pain: evidence for involvement of the 5p15.2 region. Ann Rheum Dis 72, 
427-36 (2013). 
27. Williams, F.M. et al. Genes contributing to pain sensitivity in the normal population: 
an exome sequencing study. PLoS Genet 8, e1003095 (2012). 
28. Chesler, E.J., Wilson, S.G., Lariviere, W.R., Rodriguez-Zas, S.L. & Mogil, J.S. Influences 
of laboratory environment on behavior. Nat Neurosci 5, 1101-2 (2002). 
29. Fillingim, R.B. et al. The A118G single nucleotide polymorphism of the mu-opioid 
receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 
6, 159-67 (2005). 
30. Sorge, R.E. et al. Genetically determined P2X7 receptor pore formation regulates 
variability in chronic pain sensitivity. Nat Med 18, 595-9 (2012). 
31. Lee, M. & Tracey, I. Neuro-genetics of persistent pain. Current opinion in 
neurobiology 23, 127-132 (2013). 
32. Bishop, S. & Forster, S. in The Cambridge handbook of human affective neuroscience 
(eds. Armony, J. & Vuilleumier, P.) chapter 24 (Cambridge University Press, 
Cambridge ; New York, 2013). 
33. Dulac, C. Brain function and chromatin plasticity. Nature 465, 728-35 (2010). 
34. Tajerian, M. et al. DNA methylation of SPARC and chronic low back pain. Mol Pain 7, 
65 (2011). 
35. Wu, H. & Zhang, Y. Mechanisms and functions of Tet protein-mediated 5-
methylcytosine oxidation. Genes Dev 25, 2436-52 (2011). 
36. Telese, F., Gamliel, A., Skowronska-Krawczyk, D., Garcia-Bassets, I. & Rosenfeld, M.G. 
"Seq-ing" insights into the epigenetics of neuronal gene regulation. Neuron 77, 606-
23 (2013). 
37. Buchen, L. Neuroscience: In their nurture. Nature 467, 146-8 (2010). 
38. Bell, J.T. et al. Epigenome-wide scans identify differentially methylated regions for 
age and age-related phenotypes in a healthy ageing population. PLoS Genet 8, 
e1002629 (2012). 
39. Denk, F. & McMahon, S.B. Chronic pain: emerging evidence for the involvement of 
epigenetics. Neuron 73, 435-44 (2012). 
15 
 
40. Denk, F. et al. HDAC inhibitors attenuate the development of hypersensitivity in 
models of neuropathic pain. Pain (2013). 
41. Henikoff, S. & Shilatifard, A. Histone modification: cause or cog? Trends Genet 27, 
389-96 (2011). 
42. Wang, Y. et al. Intrathecal 5-azacytidine inhibits global DNA methylation and methyl- 
CpG-binding protein 2 expression and alleviates neuropathic pain in rats following 
chronic constriction injury. Brain Research 1418, 64-69 (2011). 
43. Stresemann, C., Brueckner, B., Musch, T., Stopper, H. & Lyko, F. Functional diversity 
of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66, 2794-
800 (2006). 
44. Tajerian, M. et al. Peripheral nerve injury is associated with chronic, reversible 
changes in global DNA methylation in the mouse prefrontal cortex. PLoS One 8, 
e55259 (2013). 
45. Doehring, A., Oertel, B.G., Sittl, R. & Lotsch, J. Chronic opioid use is associated with 
increased DNA methylation correlating with increased clinical pain. Pain 154, 15-23 
(2013). 
46. Tochiki, K.K., Cunningham, J., Hunt, S.P. & Geranton, S.M. The expression of spinal 
methyl-CpG-binding protein 2, DNA methyltransferases and histone deacetylases is 
modulated in persistent pain states. Mol Pain 8, 14 (2012). 
47. Downs, J. et al. Linking MECP2 and pain sensitivity: the example of Rett syndrome. 
Am J Med Genet A 152A, 1197-205 (2010). 
48. Skene, P.J. et al. Neuronal MeCP2 is expressed at near histone-octamer levels and 
globally alters the chromatin state. Mol Cell 37, 457-68 (2010). 
49. Graur, D. et al. On the immortality of television sets: "function" in the human 
genome according to the evolution-free gospel of ENCODE. Genome Biol Evol 5, 578-
90 (2013). 
50. Low, L.A. & Fitzgerald, M. Acute pain and a motivational pathway in adult rats: 
influence of early life pain experience. PLoS One 7, e34316 (2012). 
51. Coutinho, S.V. et al. Neonatal maternal separation alters stress-induced responses to 
viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 282, 
G307-16 (2002). 
52. Moloney, R.D. et al. Early-life stress induces visceral hypersensitivity in mice. 
Neurosci Lett 512, 99-102 (2012). 
53. Beggs, S., Currie, G., Salter, M.W., Fitzgerald, M. & Walker, S.M. Priming of adult pain 
responses by neonatal pain experience: maintenance by central neuroimmune 
activity. Brain 135, 404-17 (2012). 
54. Tsang, S.W., Zhao, M., Wu, J., Sung, J.J. & Bian, Z.X. Nerve growth factor-mediated 
neuronal plasticity in spinal cord contributes to neonatal maternal separation-
induced visceral hypersensitivity in rats. Eur J Pain 16, 463-72 (2012). 
55. Doesburg, S.M. et al. Neonatal pain-related stress, functional cortical activity and 
visual-perceptual abilities in school-age children born at extremely low gestational 
age. Pain 154, 1946-1952 (2013). 
56. Hohmeister, J. et al. Cerebral processing of pain in school-aged children with 
neonatal nociceptive input: an exploratory fMRI study. Pain 150, 257-267 (2010). 
57. Reichling, D.B. & Levine, J.D. Critical role of nociceptor plasticity in chronic pain. 
Trends Neurosci 32, 611-8 (2009). 
16 
 
58. Loram, L.C. et al. Prior exposure to glucocorticoids potentiates lipopolysaccharide 
induced mechanical allodynia and spinal neuroinflammation. Brain Behav Immun 25, 
1408-15 (2011). 
59. Bogen, O., Alessandri-Haber, N., Chu, C., Gear, R.W. & Levine, J.D. Generation of a 
pain memory in the primary afferent nociceptor triggered by PKCepsilon activation 
of CPEB. J Neurosci 32, 2018-26 (2012). 
60. Johansen-Berg, H. Behavioural relevance of variation in white matter microstructure. 
Current opinion in neurology 23, 351-358 (2010). 
61. Filippini, N. et al. Differential effects of the APOE genotype on brain function across 
the lifespan. NeuroImage 54, 602-610 (2011). 
62. Tracey, I. et al. Imaging attentional modulation of pain in the periaqueductal gray in 
humans. J Neurosci 22, 2748-52 (2002). 
63. Ploner, M., Lee, M.C., Wiech, K., Bingel, U. & Tracey, I. Prestimulus functional 
connectivity determines pain perception in humans. Proc Natl Acad Sci U S A 107, 
355-60 (2010). 
64. Coghill, R.C., McHaffie, J.G. & Yen, Y.F. Neural correlates of interindividual 
differences in the subjective experience of pain. Proc Natl Acad Sci U S A 100, 8538-
42 (2003). 
65. Erpelding, N., Moayedi, M. & Davis, K.D. Cortical thickness correlates of pain and 
temperature sensitivity. Pain 153, 1602-1609 (2012). 
66. Foerster, B.R. et al. Reduced insular gamma-aminobutyric acid in fibromyalgia. 
Arthritis and Rheumatism 64, 579-583 (2012). 
67. Gwilym, S.E. et al. Psychophysical and functional imaging evidence supporting the 
presence of central sensitization in a cohort of osteoarthritis patients. Arthritis 
Rheum 61, 1226-34 (2009). 
68. Wanigasekera, V. et al. Baseline reward circuitry activity and trait reward 
responsiveness predict expression of opioid analgesia in healthy subjects. Proc Natl 
Acad Sci U S A 109, 17705-10 (2012). 
69. Baliki, M.N. et al. Corticostriatal functional connectivity predicts transition to chronic 
back pain. Nature neuroscience 15, 1117-1119 (2012). 
70. Mansour, A.R. et al. Brain white matter structural properties predict transition to 
chronic pain. Pain 154, 2160-8 (2013). 
71. Baliki, M.N., Geha, P.Y., Fields, H.L. & Apkarian, A.V. Predicting value of pain and 
analgesia: nucleus accumbens response to noxious stimuli changes in the presence 
of chronic pain. Neuron 66, 149-160 (2010). 
72. Becerra, L., Breiter, H.C., Wise, R., Gonzalez, R.G. & Borsook, D. Reward circuitry 
activation by noxious thermal stimuli. Neuron 32, 927-946 (2001). 
73. Wood, P.B. et al. Fibromyalgia patients show an abnormal dopamine response to 
pain. Eur J Neurosci 25, 3576-82 (2007). 
74. Schweinhardt, P., Seminowicz, D.A., Jaeger, E., Duncan, G.H. & Bushnell, M.C. The 
anatomy of the mesolimbic reward system: a link between personality and the 
placebo analgesic response. J Neurosci 29, 4882-7 (2009). 
75. Leknes, S. et al. The importance of context: when relative relief renders pain 
pleasant. Pain 154, 402-410 (2013). 
76. Heinricher, M.M., Tavares, I., Leith, J.L. & Lumb, B.M. Descending control of 
nociception: Specificity, recruitment and plasticity. Brain Research Reviews 60, 214-
225 (2009). 
17 
 
77. Lee, M.C., Zambreanu, L., Menon, D.K. & Tracey, I. Identifying brain activity 
specifically related to the maintenance and perceptual consequence of central 
sensitization in humans. J Neurosci 28, 11642-9 (2008). 
78. Wager, T.D. et al. Placebo-induced changes in FMRI in the anticipation and 
experience of pain. Science 303, 1162-7 (2004). 
79. Eippert, F., Finsterbusch, J., Bingel, U. & Buchel, C. Direct evidence for spinal cord 
involvement in placebo analgesia. Science (New York, N.Y.) 326, 404 (2009). 
80. Geuter, S. & Buchel, C. Facilitation of pain in the human spinal cord by nocebo 
treatment. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 33, 13784-13790 (2013). 
81. Weissman-Fogel, I. et al. Enhanced presurgical pain temporal summation response 
predicts post-thoracotomy pain intensity during the acute postoperative phase. J 
Pain 10, 628-36 (2009). 
82. Yarnitsky, D. Conditioned pain modulation (the diffuse noxious inhibitory control-like 
effect): its relevance for acute and chronic pain states. Curr Opin Anaesthesiol 23, 
611-5 (2010). 
83. Yarnitsky, D. et al. Prediction of chronic post-operative pain: pre-operative DNIC 
testing identifies patients at risk. Pain 138, 22-8 (2008). 
84. Yarnitsky, D., Granot, M., Nahman-Averbuch, H., Khamaisi, M. & Granovsky, Y. 
Conditioned pain modulation predicts duloxetine efficacy in painful diabetic 
neuropathy. Pain 153, 1193-8 (2012). 
85. De Felice, M. et al. Engagement of descending inhibition from the rostral 
ventromedial medulla protects against chronic neuropathic pain. Pain 152, 2701-9 
(2011). 
86. Wang, R. et al. Descending facilitation maintains long-term spontaneous neuropathic 
pain. J Pain 14, 845-53 (2013). 
87. Hathway, G.J., Koch, S., Low, L. & Fitzgerald, M. The changing balance of brainstem-
spinal cord modulation of pain processing over the first weeks of rat postnatal life. 
The Journal of physiology 587, 2927-2935 (2009). 
88. Hathway, G.J., Vega-Avelaira, D. & Fitzgerald, M. A critical period in the supraspinal 
control of pain: opioid-dependent changes in brainstem rostroventral medulla 
function in preadolescence. Pain 153, 775-783 (2012). 
89. Vega-Avelaira, D., McKelvey, R., Hathway, G. & Fitzgerald, M. The emergence of 
adolescent onset pain hypersensitivity following neonatal nerve injury. Mol Pain 8, 
30 (2012). 
90. Smith, Y.R. et al. Pronociceptive and antinociceptive effects of estradiol through 
endogenous opioid neurotransmission in women. J Neurosci 26, 5777-85 (2006). 
91. Vincent, K. et al. Brain imaging reveals that engagement of descending inhibitory 
pain pathways in healthy women in a low endogenous estradiol state varies with 
testosterone. Pain 154, 515-24 (2013). 
92. Tu, C.H. et al. Menstrual pain is associated with rapid structural alterations in the 
brain. Pain 154, 1718-24 (2013). 
93. Vincent, K. et al. Dysmenorrhoea is associated with central changes in otherwise 
healthy women. Pain 152, 1966-75 (2011). 
94. Labus, J.S. et al. Sex differences in emotion-related cognitive processes in irritable 
bowel syndrome and healthy control subjects. Pain 154, 2088-2099 (2013). 
18 
 
95. Moayedi, M. et al. Contribution of chronic pain and neuroticism to abnormal 
forebrain gray matter in patients with temporomandibular disorder. Neuroimage 55, 
277-86 (2011). 
96. Chen, J.Y., Blankstein, U., Diamant, N.E. & Davis, K.D. White matter abnormalities in 
irritable bowel syndrome and relation to individual factors. Brain research 1392, 121-
131 (2011). 
97. Erpelding, N. & Davis, K.D. Neural underpinnings of behavioural strategies that 
prioritize either cognitive task performance or pain. Pain 154, 2060-2071 (2013). 
98. Kuchinad, A. et al. Accelerated brain gray matter loss in fibromyalgia patients: 
premature aging of the brain? J Neurosci 27, 4004-7 (2007). 
99. Villemure, C., Ceko, M., Cotton, V.A. & Bushnell, M.C. Insular Cortex Mediates 
Increased Pain Tolerance in Yoga Practitioners. Cereb Cortex (2013). 
100. Coggon, D.I. & Martyn, C.N. Time and chance: the stochastic nature of disease 
causation. Lancet 365, 1434-7 (2005). 
101.  Mogil, J.S. Pain genetics: past, present and future. Trends Genet 28, 258-66 (2012). 
